What if you'd held BIB?
A $1,000 investment in ProShares Ultra Nasdaq Biotechnology (BIB) at the month-end close of 2010-04 would be worth $17,604 at the close of 2026-08 — +1660.4% total return, dividends reinvested. The same $1,000 in the S&P 500 would be worth $6,495.
Your scenario
Result
If you'd bought $1,000 at the start of each year
Value of $1,000 invested on January 1 of each year, held to 2026-08, dividends included.
Every year, $1,000 from 2010
| Year | Value of $1,000 | Year return |
|---|---|---|
| 2010 | $1,000 | — |
| 2011 | $1,156 | +15.6% |
| 2012 | $1,926 | +66.7% |
| 2013 | $5,001 | +159.6% |
| 2014 | $8,343 | +66.8% |
| 2015 | $9,504 | +13.9% |
| 2016 | $5,306 | -44.2% |
| 2017 | $7,455 | +40.5% |
| 2018 | $5,596 | -24.9% |
| 2019 | $8,209 | +46.7% |
| 2020 | $11,475 | +39.8% |
| 2021 | $10,784 | -6.0% |
| 2022 | $7,673 | -28.8% |
| 2023 | $7,593 | -1.1% |
| 2024 | $6,844 | -9.9% |
| 2025 | $10,898 | +59.2% |
| 2026 | $17,243 | +58.2% |
Best and worst month-end to buy
The best single month-end close to have bought BIB was 2010-06 ($5.06): $1,000 then is $24,945 today. The worst was 2026-08 ($126): $1,000 then is $1,000.
FAQ
What would $1,000 in BIB be worth today?
A $1,000 investment in ProShares Ultra Nasdaq Biotechnology (BIB) at the start of 2010 would be worth about $17,604 today, a total return of +1660.4%. Dividends are reinvested in these figures.
What were the best and worst years for BIB?
ProShares Ultra Nasdaq Biotechnology (BIB)'s strongest calendar year since 2010 was 2013, a +159.6% return — $1,000 held through that year became about $2,596 by year-end. Its weakest year was 2016, at -44.2%.
Does the calculator include dividends and splits?
Yes where available. Prices are adjusted for both stock splits and reinvested dividends (total return), the same measure brokerages use.
How much would $100 per month in BIB have grown?
Investing $100 at the end of every month since 2010-04 would have grown to about $90,012 on $19,700 invested.
Did BIB beat the S&P 500?
Over the same period, $1,000 in the S&P 500 index would be worth $6,495. BIB beat the S&P 500 by +171.0% in total return.
Is this investment advice?
No. Wall Street Regrets is an entertainment and education tool. Every number is a historical calculation, not a prediction, and past performance never guarantees future results.
Methodology
ProShares Ultra Nasdaq Biotechnology (BIB) historical total-return data from 2010-04 to 2026-08, reduced to month-end closes for the tables above.
Returns use adjusted close prices from Yahoo Finance historical data — adjusted for stock splits and reinvested dividends — the same convention used by major brokerages. A "year" scenario invests $1,000 at the prior December's month-end close and values it at the latest available month-end close. Non-USD amounts are converted at historical month-end exchange rates (Yahoo Finance): to USD on the buy date and back to your currency at the latest rate, so the return reflects the currency move as well as the asset.
Month-end resolution means intra-month extremes are not captured in tables; the calculator uses exact trading-day closes where daily data is available. Figures ignore taxes, fees, and the currency effects of non-USD listings. History is not a forecast. Wall Street Regrets is entertainment, not investment advice.
What if you'd held…
Data: adjusted close prices via Yahoo Finance. As of 2026-08. Not financial advice.